These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 11090077

  • 1. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.
    Blood; 2000 Dec 01; 96(12):3907-14. PubMed ID: 11090077
    [Abstract] [Full Text] [Related]

  • 2. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.
    Blood; 2005 Jul 01; 106(1):265-73. PubMed ID: 15769897
    [Abstract] [Full Text] [Related]

  • 3. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
    Schwäble J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, Rehage M, Rudat A, Brandts C, Berdel WE, Müller-Tidow C, Serve H.
    Blood; 2005 Mar 01; 105(5):2107-14. PubMed ID: 15536149
    [Abstract] [Full Text] [Related]

  • 4. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 5. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan 18; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
    Scheijen B, Ngo HT, Kang H, Griffin JD.
    Oncogene; 2004 Apr 22; 23(19):3338-49. PubMed ID: 14981546
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.
    Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, Naoe T.
    Leukemia; 2002 Aug 22; 16(8):1535-40. PubMed ID: 12145695
    [Abstract] [Full Text] [Related]

  • 12. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 22; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 13. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H.
    Cancer Res; 2005 Nov 01; 65(21):9643-50. PubMed ID: 16266983
    [Abstract] [Full Text] [Related]

  • 14. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H.
    Leukemia; 2008 Jan 01; 22(1):78-86. PubMed ID: 17943165
    [Abstract] [Full Text] [Related]

  • 15. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 01; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2004 Mar 15; 103(6):2266-75. PubMed ID: 14604974
    [Abstract] [Full Text] [Related]

  • 18. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
    Zheng R, Friedman AD, Small D.
    Blood; 2002 Dec 01; 100(12):4154-61. PubMed ID: 12393674
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R, Miething C, Thiede C, Peschel C, Duyster J.
    Blood; 2005 Jun 15; 105(12):4792-9. PubMed ID: 15718420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.